20:31 , Jan 18, 2019 |  BC Week In Review  |  Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
23:28 , Jan 17, 2019 |  BC Extra  |  Company News

Spectrum divesting marketed products to focus on late-stage programs

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) is selling its marketed hematology/oncology portfolio to Acrotech Biopharma LLC to focus on developing and commercializing its two remaining late-stage compounds, Rolontis eflapegrastim and poziotinib. Spectrum will receive $160 million up...
17:34 , Jan 17, 2019 |  BC Week In Review  |  Clinical News

Aslan reports gastric, biliary tract cancer data for varlitinib

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said Jan. 14 that its pan-HER inhibitor varlitinib missed the primary endpoint of a Phase II trial to treat gastric cancer. The study evaluated varlitinib as a first-line therapy in...
15:08 , Jan 14, 2019 |  BC Extra  |  Clinical News

Aslan dips after Phase II gastric cancer miss

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said its pan-HER inhibitor varlitinib missed the primary endpoint of a Phase II trial to treat gastric cancer. Aslan shares slid $2.75 (10%) to $24.90 in Taipei on Monday, and...
20:45 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

China's National Medical Products Administration (NMPA) conditionally approved on Dec. 17 the first domestic anti-PD-1 mAb, Tuoyi toripalimab (JS001) from Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China), as second-line treatment of melanoma. The news comes...
20:19 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

No breakthrough therapy designation for Spectrum's poziotinib

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) lost $4.05 (39%) to $6.39 on Dec. 20 after announcing after market close on Dec. 19 that based on data from an investigator-sponsored Phase II trial FDA did not grant breakthrough...
22:38 , Dec 17, 2018 |  BC Extra  |  Company News

China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

China's National Medical Products Administration (NMPA) conditionally approved on Monday the first domestic anti-PD-1 mAb, Tuoyi toripalimab (JS001) from Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China), as second-line treatment of melanoma. The news comes as...
19:18 , Nov 1, 2018 |  BC Innovations  |  Translation in Brief

Private sharing

A new cryptographic computational protocol from the Massachusetts Institute of Technology will allow drug companies to pool data for predictive modeling of drug-target interactions without revealing the underlying drugs, targets or observed interactions. The method...
18:57 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said on Oct. 19 that FDA and EMA have both pushed back their reviews of anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line non-small cell lung cancer. The...
23:32 , Oct 19, 2018 |  BC Extra  |  Company News

FDA, EMA delay review of Opdivo/Yervoy for first-line NSCLC

Bristol-Myers Squibb Co. (NYSE:BMY) said Friday that FDA and EMA have both pushed back their reviews of anti-PD-1 mAb Opdivo nivolumab plus anti-CTLA-4 mAb Yervoy ipilimumab for first-line non-small cell lung cancer. The company also...